Last reviewed · How we verify

Long- and intermediate- acting insulins — Competitive Intelligence Brief

Long- and intermediate- acting insulins (Long- and intermediate- acting insulins) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

phase 2 Small molecule Live · refreshed every 30 min

Target snapshot

Long- and intermediate- acting insulins (Long- and intermediate- acting insulins) — Biologics & Biosimilars Collective Intelligence Consortium.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Long- and intermediate- acting insulins TARGET Long- and intermediate- acting insulins Biologics & Biosimilars Collective Intelligence Consortium phase 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Long- and intermediate- acting insulins — Competitive Intelligence Brief. https://druglandscape.com/ci/long-and-intermediate-acting-insulins. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: